Clinical Trial

A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 25, 2021 (before its estimated October 20, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.
Trial Details
NCT Number NCT05091541
Lead Sponsor Nanjing IASO Biotechnology Co., Ltd.
Conditions B-cell Non-Hodgkin's Lymphoma
Enrollment 125 participants
Start Date 2021-10-20
Primary Completion 2024-10-20 (estimated)
Study Completion 2039-10-20 (estimated)
Updated on ClinicalTrials.gov 2021-10-25